Monoclonal Antibody Therapies for Hematological Malignancies: Not Just Lineage-Specific Targets.

ABSTRACT: Today, monoclonal antibodies (mAbs) are a widespread and necessary tool for biomedical science. In the hematological cancer field, since rituximab became the first mAb approved by the Food and Drug Administration for the treatment of B-cell malignancies, a number of effective mAbs targeting lineage-specific antigens (LSAs) have been successfully developed. Non-LSAs (NLSAs) are molecules that are not restricted to specific leukocyte subsets or tissues but play relevant pathogenic roles in blood cancers including the development, proliferation, survival, and refractoriness to therapy of tumor cells. In consequence, efforts to target NLSAs have resulted in a plethora of mAbs-marketed or in development-to achieve different goals like neutralizing oncogenic pathways, blocking tumor-related chem

SUBMITTER: Cuesta-Mateos C 

PROVIDER: S-EPMC5776327 | biostudies-literature | 2017

REPOSITORIES: biostudies-literature